Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development 2nd Edition 2019 at Meripustak

Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development 2nd Edition 2019

Books from same Author: Andrew J Krentz

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Price: ₹ 14687.00/- [ 25.00% off ]

    Seller Price: ₹ 11015.00

Sold By: Store4Doctors      Click for Bulk Order

Offer 1: Get 25.00 % + Flat ₹ 75 discount on shopping of ₹ 500 [Use Code: MPSTK75]

Offer 2: Get 25.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 25.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Andrew J Krentz
    PublisherSpringer
    Edition2nd
    ISBN9783030117474
    Pages556
    BindingHardcover
    LanguageEnglish
    Publish YearMay 2019

    Description

    Springer Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development 2nd Edition 2019 by Andrew J Krentz

    "This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders.

     Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs.

     This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic d..."